- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Merck launches production of its anti-diabetes medicine in Algeria
18 November 2015 • Author: Victoria White
Merck and Novapharm have announced a joint venture in Algeria to produce Merck’s diabetes and high blood pressure treatments for the Algerian market.
The investment is valued at EUR 5 million and will enable Algeria to reduce the import bill for medicines.
With an annual production capacity of 500 million tablets for the Algerian market, the production unit located in Bou Ismail, a remote village 40 km west of Algiers, will also help increase national production capacity.
“Our partnership with Novapharm will optimise our services for Algerian patients. It will establish improved access to quality medicines,” said Mr. Bernd Reckmann, Member of the Board of Directors and Chairman of the Management Board of Life Science and Performance Materials at Merck. “By sharing good manufacturing practices and transfer of technology and know-how, this alliance between Merck and Novapharm will have a positive impact on production capacity and the future of the pharmaceutical industry in Algeria.”
The venture will increase availability of medicines in the local market
“We are proud that today our medicines are produced by Algerians for Algerians, with a manufacturing and control process identical to that used at our sites in Europe,” said Moncef Meklati, CEO of Merck in Algeria.
The partnership intends to improve the care of patients through increased availability of medicines in the local market. In the long term, it will also create 200 jobs.
For his part, Mr. Yassine Benamara, CEO of Novapharm Production, claims that this partnership has resulted in a transfer of technology and know-how to the benefit of Algeria. “This joint venture complies with the government guidelines which expect to fulfil national requirements to the tune of 70% thanks to local pharmaceutical production in 2016.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics